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Abstract 
Human testicular germ cell tumors (TGCTs) are histologically heterogenous 
neoplasms with variable malignant potential. Two main groups of germ cell tumors occur 
in men: seminomas and nonseminomas. In the present study a set of four tumor 
suppressor genes was investigated in testicular cancers. CDH1, APC, p53 and nm23-H1 
genes were tested for the loss of heterozygosity (LOH). Thirtyeight testicular germ cell 
tumors (17 seminomas and 21 nonseminomas) were analyzed by PCR using restriction 
fragment length polymorphism or dinucleotide/tetranucleotide repeat polymorphism 
method. An allelic loss of p53 at exon 4 was detected in five nonseminomas, whereas 
LOH of p53 at intron 6 occured in one of the seminoma and two of the nonseminoma 
samples. Allelic losses of the APC gene were present in three seminomas and one 
nonseminoma, whereas one seminoma and three nonseminomas showed LOH of CDH1. 
The analysis of allelic losses has shown no common structural genetic alterations in 
tumor tissues, although a different pattern of LOH has been observed between the two 
main histological groups of TGCTs. 
 
Introduction 
Testicular germ cell tumors (TGCTs) are the most common tumors in young men. 
It is generally accepted that the TGCTs originate from intratubular germ cell neoplasia 
(ITGCN). Histologically and clinically, TGCTs are classified into seminomas and 
nonseminomas. About 50% of TGCTs are pure seminomas, and 40% are pure or mixed 
nonseminomas. The remaining 10% containing both seminoma and nonseminoma 
components are classified as being nonseminomas according to the WHO 2004 
classification system [4]. 
Seminomas develop from the sperm-producing germ cells of the testicle. The two 
main types of seminomatous tumors are classic seminoma and spermatocytic seminoma. 
Seminoma is the most common testicular germ cell neoplasm and usually occurs in 
patients in the fourth decade of life. 
There are four main types of nonseminomatous tumors: embryonal carcinoma, 
yolk sac tumor, immature or mature teratoma and choriocarcinoma. These tumor types 
are often seen together in various combinations, referred to as mixed TGCTs, which may 
also include a seminoma component [1]. The undifferentiated stem cells of 
nonseminomas are termed embryonal carcinoma cells and can differentiate into a broad 
spectrum of somatic tissues (teratomas) and the extraembryonal derivates: yolk sac 
tumors and choriocarcinomas [15]. Nonseminoma occurs most frequently between 20 
and 40 years of age. 
Molecular genetic studies of TGCTs have reported allele loss on chromosomes 1, 
3, 5, 9, 11, 12, 13, 17 and 18. However, mutation analyses of candidate tumor suppressor 
genes such as RB, TP53, WT1, BRCA1, APC, CDH1, MCC, NF2 and DCC have 
demonstrated only rare alterations, so major TGCT suppressor genes are yet to be 
identified [10]. To date the exact cellular and molecular mechanisms leading to the 
neoplastic progression of ITGCN are still not fully understood [13]. Increasing evidence 
suggests that carcinogenesis must be understood in terms of an accumulation of 
mutations in regulatory genes, including activation of oncogenes and inactivation or loss 
of tumor suppressor genes. 
APC and E-cadherin proteins are components of the adherens junction, where E-
cadherin is bound to β-catenin, which in turn binds to the central part of the APC. 
Besides their roles in cellular architecture, the APC and β-catenin play a signaling role as 
components of the Wnt signal transduction pathway [17]. APC acts as a negative 
regulator of the Wnt signaling pathway, being a critical component of the β-catenin 
destruction machinery heading to the proteasome. E-cadherin has a role in Wnt signaling, 
too; where it acts as an indirect modulator of Wnt signaling. Since it binds to and 
sequesters cytoplasmic β-catenin, it is involved in the modulation of the signal [16]. 
These genes are also implicated in cancer, especially in neoplasms of epithelial origin. 
Several studies have suggested that TGCTs express high levels of wild type p53 
protein but apparently do not contain p53 mutations [6], [7]. The p53 pathway responds 
to a variety of intrinsic and extrinsic stress signals and when activated maintains cellular 
integrity by inducing cell arrest, senescence or apoptosis. It has been shown that β-
catenin and p53 form a negative feedback loop that regulates Wnt signaling. β-catenin 
induces p53 activation by inducing p14ARF expression, p14ARF inhibits Mdm2 and 
consequently leads to an accumulation of active p53 [3]. 
Nucleoside diphosphate (NDP) kinases, responsible for the synthesis of 
nucleoside triphosphates and produced by the nm23 genes, are involved in numerous 
regulatory processes associated with cell growth, differentiation, tumor progression, 
metastasis and development. Nm23-H1 is overexpressed in solid tumors as compared to 
normal tissues with a reduced expression correlated with the metastatic potential of some 
tumors [5]. The immunohistochemically detected expression of both the nm23-H1 and -
H2 gene products is not associated with the metastatic status or the invasive status of 
testicular seminoma [11]. 
Our objective was to examine the loss of heterozygosity (LOH) of APC, CDH1 
(E-cadherin), p53 and nm23-H1 tumor suppressor genes in 38 TGCTs (17 seminomas 
and 21 nonseminomas). Gene products of APC, CDH1 and p53 are involved in the Wnt 
signaling pathway implicated in embryogenesis and cancerogenesis, whereas the role of 
nm23-H1 protein in the development of TGCTs has not been elucidated. 
 
Materials and Methods 
Patients and tumor material. Thirtyeight TGCTs (17 seminomas and 21 
nonseminomas) were collected from the Sisters of Mercy University Hospital and 
University Hospital Center, Zagreb, Croatia. The samples were formalin-fixed and 
paraffin-embedded. Clinical and pathological data for 38 TGCTs according to the WHO 
2004 classification are shown in Table 1. 
DNA extraction. For each specimen, a 20 µm paraffin-embedded section was 
prepared for DNA extraction. In addition, a 4 µm section was stained with hemalaun-
eosin to identify the tumor and normal tissue areas which were removed separately from 
the microscopic slide, transferred to microtubes and extracted using QIAamp DNA Mini 
Kit (Qiagen, Germany). 
LOH analysis of APC, p53, CDH1 and nm23-H1 genes. LOH of APC and p53 
genes were detected using polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) method (Table 2). PCR of APC gene exon 11 amplified a 
133-bp target sequence containing a polymorphic RsaI restriction site, with restriction 48- 
and 85-bp fragments (heterozygous alleles). The reaction mixture for APC exon 11 
amplification was: 2 µmol of each primer (Operon Biotechnologies, Germany), 0.2 mM 
of each dNTP, 100 ng DNA, 0.4 U Taq polymerase (Fermentas, Lithuania), 2 mM 
MgCl2, 1x reaction buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.8). PCR was performed 
for 45 cycles under the following conditions: initial denaturation, 3 min/96ºC; 
denaturation, 30 sec/96ºC; annealing, 30 sec/58ºC; extension, 30+1 sec/72ºC; final 
extension, 10 min/72ºC. PCR aliquots (10-20 µl) were digested with 5 U RsaI 
(Fermentas, Lithuania) for 12 hours. A Bsh1236I restriction site in exon 4 and MspI 
restriction site in intron 6 of the p53 were examined as previously mentioned [12]. 
Analyses of the D16S752 tetranucleotide microsatellite marker linked to CDH1 
and M2 dinucleotide microsatellite marker linked to nm23-H1 were carried out by PCR 
using 5 pmol of each primer (Table 2), under the APC PCR conditions. Obtained 
fragments were analyzed on silver-stained 15% polyacrylamide gel. Loss of 
heterozygosity of CDH1 and nm23-H1 was considered to occur if one out of two alleles 
(heterozygous samples) of gene markers was missing or significantly reduced in 
comparison to alleles from adjacent normal tissue. 
 
Results 
Genetic studies were performed for the presence of possible allelic losses of APC, 
p53, CDH1 and nm23-H1 tumor suppressor genes. 
First, the RsaI polymorphic site in APC's exon 11 was analyzed. From 38 TGCTs, 
29 samples (76%, 13 seminomas and 16 nonseminomas) were informative for this 
polymorphism. Four (14%) samples: three seminomas (23%) and one nonseminoma (6%) 
demonstrated LOH (Tables 3 and 4). These tumor samples showed either only one band, 
a 133-bp fragment (Fig. 1), or two bands (48-bp and 85-bp fragments). 
Two polymorphic sites of p53 gene, a Bsh123GI restriction site in exon 4 and a 
MspI restriction site in intron 6, were used. Analysis of these two markers showed that 30 
tumors (79%, 12 seminomas and 18 nonseminomas) were heterozygous for the first 
polymorphism. Loss of heterozygosity was observed in five (28%) nonseminoma cases as 
one of the alleles missing in comparison to bands from the adjacent normal testis tissue 
(Fig. 2, Tables 3 and 4). The polymorphic marker in intron 6 of the p53 was less 
informative than the first one. Twenty out of 38 samples (53%, 12 seminomas and 8 
nonseminomas) were heterozygous. Allelic loss was found in three (15%) tumors: one 
seminoma (8%) and two nonseminomas (25%); Fig. 3, Tables 3 and 4.  
The D16S752 polymorphic marker linked to the CDH1 gene was analyzed. From 
38 TGCTs, 20 tumors (53%, 9 seminomas and 11 nonseminomas) were informative. Our 
analysis revealed that four (20%) samples: one seminoma (11%) and three 
nonseminomas (27%), had LOH of the CDH1 when tumor DNA was compared to 
autologous normal testis tissue DNA (Fig. 4, Tables 3 and 4). 
The result of nm23-H1 repeat polymorphism analysis demonstrated no changes of 
the gene among 34 (89%) informative TGCTs (15 seminomas and 19 nonseminomas). 
Although we observed moderate levels of allelic losses of p53 and CDH1 genes in 
nonseminomas, and moderate level of LOH of APC gene in seminomas (Table 4), there 
are no statistically significant differences in LOHs between seminomas and 
nonseminomas found using Fisher's exact test due to the small number of samples. 
 
Discussion 
Human tumorigenesis is a multistep process. For some cancers there is 
considerable knowledge of the molecular events associated with progression from early 
precursor lesions to metastatic cancer. Although knowledge of the pathogenesis of 
TGCTs is more limited, a multistep model with the progression from ITGCN to 
seminoma and then to nonseminoma has been widely proposed. However, the specific 
gene alteration events that might determine the progression from ITGCN to 
nonseminoma are ill-defined [10]. 
The majority of infantile testis tumors, seminomas and nonseminomas, show a 
biallelic expression of imprinted genes. These data support the hypothesis that these germ 
cell tumors originate from an early erased germ cell [15]. If a loss of genomic imprinting 
affects a tumor suppressor gene, one allele is already inactivated due to the passage 
through either a male or a female germ line.  
Recently, a novel model for examing testicular teratomas has been identified [19]. 
This model indicates that Wnt signaling is able to induce teratomas in p53 mutant cells 
and suggests that a single copy of the p53 gene is sufficient for blocking tumorigenesis in 
male germ cells.  
In the present study, we investigated allelic losses of APC, CDH1, p53 and nm23-
H1 genes to elucidate whether LOHs of these genes are linked to a particular 
phenomenon of the signaling pathway disruption or are a consequence of whole genome 
instability in view of the high number and variety of chromosome abnormalities, 
including deletions and rearrangements present in TGCTs [2]. 
It is important to mention that we tested more nonseminoma than seminoma 
samples (17 seminomas and 21 nonseminomas), but only informative (heterozygous) 
samples were calculated. The number of informative samples for single genetic marker 
does not differ significantly between two main histological groups of TGCTs (Table 4). 
Exon 4 of the p53 gene is involved in induction of apoptosis, whereas changes in 
intron 6 are implicated in its expression by protein stabilization. A moderate level (28%) 
of allelic loss of the p53 in nonseminomas suggests that loss of this gene may contribute 
to their development. Previously, Peng et al. [18] have observed a LOH of p53 gene in 
22% of TGCTs, despite the fact that mutations within the coding region of p53 rarely 
occur in testis cancer. However, they have not observed the discrepancies between two 
different markers in the same gene in terms of LOH scoring in seminomas and 
nonseminomas (20% versus 26%, respectively). 
In self-renewing tissues such as colon and testis, the APC protein is thought to 
modulate the stem cell differentiation by controlling the β-catenin /Tcf-Lef pathway in 
which APC targets β-catenin for degradation. To date, the function of APC in human 
testes is unclear [14]. Most mutations of the APC gene are frameshift mutations, 
however, it is recognised that a number of tumors demonstrated LOH of this gene. 
Peng et al. [18] observed that LOH occured in 28% of informative cases at APC 
gene. However, they did not detect statistically significant differences in LOH of APC, by 
using two different markers in the same gene, between the seminomas and 
nonseminomas (31% versus 25%, respectively). 
To increase both informativity and sensitivity, we examined the MspI restriction 
site polymorphism in APC's exon 15, a 550 bp target sequence containing a polymorphic 
MspI restriction site with restriction to two 250 bp fragments (heterozygous alleles). 
However, the PCR amplification of APC's exon 15 was unsuccessful. In general, it is 
particulary difficult to amplify DNA from paraffin-embedded tissue when the amplified 
fragment is larger than 300 bp, perhaps due to degradation of the DNA. Therefore, we 
have not searched for two different markers in the same gene (with the exception of p53, 
those markers are presented separately), to avoid any influence on the outcome of the 
results. 
E-cadherin has been viewed as a tumor suppressor, mainly by maintaining cell-
cell adhesion and anchoring β-catenin in a submembranous location [16]. Mutations of 
CDH1 gene have been found in a number of tumors, but not in testicular cancers. 
Although two groups of authors [21], [9] reported increased expression of CDH1 in 
nonseminomas compared to seminomas, and Sonne et al. [23] observed increased 
expression of CDH1 in both seminomas and nonseminomas from pateints with stage 
II/III disease, Heidenreich et al. [8] proposed a correlation between loss of E-cadherin 
and lymph node metastases in stage I nonseminomas. However, Honecker et al. [9] have 
found that neither vascular invasion nor the frequency of metastatic spread correlate with 
E-cadherin expression. 
Interestingly, in our study one seminoma with CDH1 allelic deletion also 
demonstrated allelic loss of APC's exon 11. Furthermore, one nonseminoma with p53 
exon 4 allelic deletion demonstrated LOH of the CDH1 gene (Table 3). Allelic losses of 
both CDH1 and p53 genes are more prominent in nonseminomas, which may contribute 
to their increased genomic instability and invasivness. All LOHs of the p53, except for 
one, were found in tumors with an embryonal carcinoma component, and all cases of 
CDH1 LOHs in nonseminoma were found in tumors with a yolk sac tumor component. 
Both are highly invasive types of nonseminomas. The majority of CDH1 LOHs were 
found in T2 and T3 stage tumors, which might be because it is either a late occurence in 
the tumorigenesis, or it has a role in the invasiveness of these tumors. 
Although nm23 proteins are expressed in testis germinal cells, studies on 
mutations and expression of the nm23-H1 and nm23-H2 genes in TGCTs have failed to 
establish a significant role in the development of these tumors [22]. In accordance with 
these findings, we did not find aberrations of nm23-H1 in TGCTs. 
In the present study, analysis of allelic losses has shown no common structural 
genetic alterations in tumor tissues. Different pattern of LOH has been observed between 
two main histological groups of TGCTs, in agreement with the data published by Rothe 
et al. [20]. Occurrence of LOHs within two main groups of TGCTs turned out to be either 
6–11% or 23-28% for examined gene markers. These LOH rates correspond to 
cytogenetically normal and abnormal chromosomes, respectively [18]. Although we have 
not performed cytogenetic analysis, our results suggest that different chromosomal 
aberrations are present in two main groups of TGCTs. Since we observed neither LOHs 
of nm23-H1 nor BRCA1 (unpublished results), both located on chromosome 17q, we 
believe the short arm of chromosome 17 is involved in cytogenetic changes of TGCTs. 
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Fig. 1. Loss of heterozygosity of the APC gene at exon 11. Silver-stained 15% 
polyacrylamide gel. Lane 1: ΦX174 DNA/BsuRI (Fermentas, Lithuania); lane 2: 
heterozygous normal testis tissue (48-, 85- and 133-bp fragments); lane 3: allelic loss in 
the corresponding testicular germ cell tumor (patient no. 15; 133-bp fragment). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Loss of heterozygosity of the p53 gene at exon 4. Silver-stained 15% 
polyacrylamide gel. Lane 1: 50-bp DNA ladder (Fermentas, Lithuania); lane 2: 
heterozygous normal testis tissue (87-, 160- and 247-bp fragments); lane 3: allelic loss in 
the corresponding testicular germ cell tumor (patient no. 37; 87- and 160-bp fragments). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Loss of heterozygosity of the p53 gene at intron 6. Silver-stained 15% 
polyacrylamide gel. Lane 1: ΦX174 DNA/BsuRI (Fermentas, Lithuania); lane 2: 
heterozygous normal testis tissue (44-, 63- and 107-bp fragments); lane 3: allelic loss in 
the corresponding testicular germ cell tumor (patient no. 30; 44- and 63-bp fragments). 
 
 
 
 
 
Fig. 4. Loss of heterozygosity of the CDH1 gene at D16S752 polymorphic marker. 
Silver-stained 15% polyacrylamide gel. Lane 1: 50-bp DNA ladder (Fermentas, 
Lithuania); lane 2: heterozygous normal testis tissue; lane 3: allelic loss in the 
corresponding testicular germ cell tumor (patient no. 27). 
 
Table 1. Clinical and pathological data for 38 testicular germ cell tumor cases. 
Patient no. Age pTNM Histology 
1 26 pT1NXMX ITGCN, S 
2 26 pT1NXMX ITGCN, S 
3 37 pT1NXMX S 
4 33 pT1NXMX ITGCN, S 
5 31 pT1NXMX ITGCN, S 
6 29 pT1NXMX ITGCN, S 
7 39 pT1NXMX ITGCN, S 
8 27 pT3NXMX S 
9 41 pT1NXMX ITGCN, S 
10 48 pT1NXMX S 
11 48 pT2NXMX S 
12 34 pT1NXMX ITGCN, S 
13 60 pT1NXMX ITGCN, S 
14 29 pT1NXMX ITGCN, S 
15 60 pT1NXMX S 
16 28 pT1NXMX ITGCN, S 
17 32 pT1NXMX ITGCN, S 
18 37 pT1NXMX EC 
19 18 pT2NXMX EC, IT, MT, S 
20 24 pT1NXMX EC, ITGCN, S 
21 37 pT1NXMX EC, ITGCN, S 
22 28 pT2NXMX C, EC, IT, MT 
23 17 pT2NXMX EC, MT 
24 34 pT2NXMX EC 
25 19 pT1NXMX EC, ITGCN, MT, YST 
26 39 pT1NXMX MT, YST 
27 21 pT2NXMX EC, MT, YST 
28 23 pT2NXMX EC, IT, MT 
29 22 pT1NXMX MT, YST 
30 25 pT3NXMX EC 
31 45 pT2NXMX EC, ITGCN, S, YST 
32 NK pT2NXMX C, EC, ITGCN, S, YST 
33 23 pT2NXMX EC, IT, ITGCN, MT, YST 
34 39 pT1NXMX EC, ITGCN, S, YST 
35 24 pT2NXMX EC, ITGCN, YST 
36 30 pT1NXMX EC, ITGCN, YST 
37 36 pT1NXMX EC, ITGCN, MT, YST 
38 58 pT2NXMX EC, ITGCN, YST 
C-choriocarcinoma; EC-embryonal carcinoma; IT-immature teratoma; ITGCN-intratubular germ cell 
neoplasia; MT-mature teratoma; S-seminoma; YST-yolk sac tumor; NK-not known 
Table 2. The sequences of pairs of primers used in the PCR reaction followed by LOH analysis of CDH1, APC, p53 and nm23-H1 
genes. 
Gene Amplimer 
size (bp) 
Tandem 
repeat 
Restriction enzyme; 
Incubation 
temperature 
Nucleotide sequence 
recognized by 
enzyme 
Heterozygous alleles (bp)/ 
Homozygous alleles (bp) 
Primer sequence (5'-3') 
CDH1 D16S752 102-126 GATA    
AATTGACGGTATATCTATCTGTCTG
GATTGGAGGAGGGTGATTCT 
nm23-H1 M2 110-120 CA    
TATGAGTTCAACTACGCACG 
CTCGAGCACAGGAGCAGGTT 
APC exon 11 133  RsaI; 37°C 
5'-GT↓AC-3' 
3'-CA↑TG-5' 
48, 85, 133/ 
48, 85; 133 
GGACTACAGGCCATTGCAGAA 
GGCTACATCTCCAAAAGTCAA 
p53 exon 4 247  Bsh1236I; 37°C 
5'-CG↓CG-3' 
3'-GC↑GC-5' 
87, 160, 247/ 
87, 160; 247 
GATGCTGTCCGCGGACGATAT 
CGTGCAAGTCACAGACTTGGC 
p53 intron 6 107  MspI; 37°C 
5'-C↓CGG-3' 
3'-GGC↑C-5' 
44, 63, 107/ 
44, 63; 107 
AGGTCTGGTTTGCAACTGGG 
GAGGTCAAATAAGCAGCAGG 
 
Table 3. Loss of heterozygosity (LOH) of APC, p53 and CDH1 genes in testicular germ cell tumors. 
Patient no., 
tumor group 
APC exon 11 p53 exon 4 p53 intron 6 CDH1 D16S752 
1, S 
8, S 
12, S 
15, S 
18, NS 
19, NS 
23, NS 
27, NS 
28, NS 
29, NS 
30, NS 
32, NS 
35, NS 
37, NS 
LOH 
LOH 
I 
LOH 
NI 
I 
NI 
I 
LOH 
I 
I 
I 
I 
I 
NI 
I 
NI 
I 
LOH 
LOH 
LOH 
LOH 
I 
I 
NI 
I 
I 
LOH 
I 
I 
LOH 
I 
I 
NI 
I 
NI 
NI 
NI 
LOH 
LOH 
NI 
I 
I 
LOH 
NI 
NI 
I 
NI 
I 
LOH 
NI 
LOH 
I 
I 
LOH 
NI 
S, seminoma; NS, nonseminoma; I, informative (heterozygous); NI, not informative (homozygous)
Table 4. The percentage of LOH of CDH1, APC, p53 and nm23-H1 tumor suppressor genes in testicular germ cell tumors. 
Tumor CDH1 D16S752 APC exon 11 p53 exon 4 p53 intron 6 nm23-H1 M2 
Seminoma, Σ 17 11% (1/9) 23% (3/13) 0% (0/12) 8% (1/12) 0% (0/15) 
Nonseminoma, Σ 21 27% (3/11) 6% (1/16) 28% (5/18) 25% (2/8) 0% (0/19) 
Numbers in parentheses: the number of tumors demonstrating LOH over the number of informative tumors 
